Product Description
antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9; selective CAIX antibody-drug conjugate CAIX-ADC (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22147747/)
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01028755 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-04-01 |
|
NCT01065623 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2010-08-01 |